Fundraising Fox
Alexza Pharmaceuticals
Mountain View, US · Founded 2000 · 82 employees on LinkedIn · 2 known investors
Find your way into Alexza Pharmaceuticals
Sign up to see every warm intro you have to Alexza Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alexza Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve. Its Staccato platform and assets were acquired by Lee's Pharmaceutical Holdings.
Founders & leadership
MK
Mark K OkiSVP, Finance & Chief Financial Officer2012–2015Mark K Oki held an executive officer position at Alexza Pharmaceuticals, where he worked on the Staccato drug-delivery platform and managed corporate finance, regulatory compliance, and capital raising activities for the biopharmaceutical company.
TB
Thomas B KingExecutiveThomas B King is an executive with more than 40 years of experience in biopharmaceutical and life sciences companies, having held CEO, President, Executive Chair, and Board Chair roles at public and private biotechnology and specialty pharmaceutical firms. He has led product development and commercialization efforts and served as a strategic advisor to the sector.
MJ
Michael J SimmsExecutive
JV
James V CassellaExecutive
Board
IS
Isaac SteinBoard director
JL
J Leighton ReadBoard director
DR
Deepika R PakianathanBoard director
SD
Samuel D. ColellaBoard director
AL
Andrew L BusserBoard director
JK
J Kevin BuchiBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$16.1M disclosed across 5 rounds · 2012–2016
▶$5MraisedFeb 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedFeb 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Isaac SteinDirector
- Deepika R PakianathanDirector
- Joseph L TurnerDirector
- Thomas B KingExecutive Officer, Director
- J Leighton ReadDirector
- Gordon RingoldDirector
- Edwin S KamemotoExecutive Officer
- J Kevin BuchiDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$143.8KraisedSep 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$143.8KraisedSep 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edwin S KamemotoExecutive Officer
- Mark K OkiExecutive Officer
- Isaac SteinDirector
- J Kevin BuchiDirector
- J Leighton ReadDirector
- Thomas B KingExecutive Officer, Director
- Deepika R PakianathanDirector
- Gordon RingoldDirector
- Joseph L TurnerDirector
- Offering amount
- $143.8K
- Amount sold
- $143.8K
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedOct 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedOct 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark K OkiExecutive Officer
- Robert A LippeExecutive Officer
- Gordon RingoldDirector
- Isaac SteinDirector
- James V CassellaExecutive Officer
- Joseph L TurnerDirector
- Deepika R PakianathanDirector
- Edwin S KamemotoExecutive Officer
- Thomas B KingExecutive Officer, Director
- J Leighton ReadDirector
- J Kevin BuchiDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5KraisedMar 2014 · 9 investors · PharmaceuticalsRule 506(b)
▶$3.5KraisedMar 2014 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gordon RingoldDirector
- J Leighton ReadDirector
- James V CassellaExecutive Officer
- Robert A. LippeExecutive Officer
- Michael J SimmsExecutive Officer
- Thomas B KingExecutive Officer, Director
- Deepika R PakianathanDirector
- Mark K OkiExecutive Officer
- J Kevin BuchiDirector
- Isaac SteinDirector
- Joseph L. TurnerDirector
- Offering amount
- $3.5K
- Amount sold
- $3.5K
- Sales commissions
- $240
- Placement agents
- Morgan Stanley & Co. LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMar 2012 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedMar 2012 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph L TurnerDirector
- Thomas B KingExecutive Officer, Director
- Michael J SimmsExecutive Officer
- James V CassellaExecutive Officer
- Mark K OkiExecutive Officer
- Deepika R PakianathanDirector
- Isaac SteinDirector
- Hal V BarronDirector
- Samuel D. ColellaDirector
- J Leighton ReadDirector
- Andrew L BusserDirector
- Gordon RingoldDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Mar 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Alexza Pharmaceuticals do?
- Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve. Its Staccato platform and assets were acquired by Lee's Pharmaceutical Holdings.
- Who are Alexza Pharmaceuticals's investors?
- Alexza Pharmaceuticals's investors include 5AM Ventures, New Enterprise Associates (NEA).
- How much funding has Alexza Pharmaceuticals raised?
- Alexza Pharmaceuticals has disclosed $16.1M raised across 5 rounds.
- Where is Alexza Pharmaceuticals headquartered?
- Alexza Pharmaceuticals is headquartered in Mountain View, US.